Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rh... (entosa (RP) is an inherited disease that...)

Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island

Date:10/21/2008

entosa (RP) is an inherited disease that causes the retina's rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP.

Age-related macular degeneration (AMD) is a chronic progressive disease of the macula that results in the loss of central vision. It is the leading cause of blindness in elderly people in the developed world. There are two forms of AMD.dry and wet. Dry AMD is the most common form of AMD representing approximately 90% of all AMD cases. In its later stages dry AMD can lead to the degeneration of photoreceptors and retinal pigment epithelial cells, a chronic condition called geographic atrophy (GA). GA affects approximately 1 million people in the United States for which there currently are no effective treatments.

About Encapsulated Cell Technology

Neurotech's core technology platform is Encapsulated Cell Technology (ECT), a unique technology that allows for the long term, sustained delivery of therapeutic factors to the back of the eye. ECT implants consist of cells that have been genetically modified to produce a specific therapeutic protein and are encapsulated in a semi-permeable hollow fiber membrane. The diffusive characteristics of the hollow fiber membrane are designed to promote long-term cell survival by allowing the influx of oxygen and nutrients while simultaneously preventing direct contact of the encapsulated cells with the cellular and molecular elements of the immune system. The cells continuously produce the therapeutic protein which diffuses out of the implant at the target site. ECT therefore enables the controlled, continuous delivery of therapeutic factors directly to the retina, bypassing the blood-retina barrier.

About Neurotech Pharmaceuticals, Inc.
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. ORIMtec Releases Industry's First Intraoperative Monitoring Reference Guide for Neurotechnologists
2. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
3. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes
11. ADVENTRX Announces Restructuring and Cost Reduction Initiatives

Post Your Comments:

Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rh...(entosa (RP) is an inherited disease that...)